Results 31 to 40 of about 13,357,463 (271)

Search for predictors of achieving minimal disease activity during tofacitinib therapy in patients with psoriatic arthritis

Современная ревматология, 2023
Objective: to search predictors of achieving minimal disease activity (MDA) during therapy in patients with psoriatic arthritis (PsA).Materials and methods.
L. D. Vorobyova, T. V. Korotaeva, S. I. Glukhova, E. Yu. Loginova, E. E. Gubar, Yu. L. Korsakova   +5 more
doaj   +1 more source

Comparative efficacy of tofacitinib and adalimumab in patients with psoriatic arthritis in real clinical practice. Data from the Russian nationwide register of patients with psoriatic arthritis

Современная ревматология, 2021
Objective: to compare the clinical efficacy in real clinical practice of the targeted synthetic disease-modifying antirheumatic drug (sDMARD) tofacitinib (TOFA) and the biologic DMARD (bDMARD), an inhibitor of tumor necrosis factor alpha (TNFα ...
E. Yu. Loginova, T. V. Korotaeva, E. E. Gubar, Yu. L. Korsakova, S. I. Glukhova, E. A. Vasilenko, A. A. Vasilenko, N. A. Kuznetsova, I. M. Patrikeyeva, E. L. Nasonov   +9 more
doaj   +1 more source

Prognostic factors associated with achieving minimal disease activity in early psoriatic arthritis patients treated according to “treat-to-target” st rategy within 12 months

Научно-практическая ревматология, 2022
Background. The goal of “treat-to-target” strategy (T2T) in psoriatic arthritis (PsA) is attaining remission or minimal disease activity (MDA). The benefits of T2T are shown recently in the study TICOPA and REMARCA. But prognostic factors for achievement
E. Yu. Loginova, T. V. Korotaeva, E. E. Gubar, S. I. Glukhova   +3 more
doaj   +1 more source

Effects of Treatment with Risankizumab on Minimal Disease Activity and Disease Activity in Psoriatic Arthritis: An Analysis of the KEEPsAKE-1 and -2 Trials

, 2022
Background/Purpose: Risankizumab (RZB) is a monoclonal antibody that specifically inhibits interleukin 23. Methods: KEEPsAKE-1 and -2, double-blind, phase 3 trials, evaluated the efficacy of RZB versus placebo (PBO) for the treatment of adult ...
Douglas, Kevin, Stakias, Vassilis, McInnes, Iain B, Merola, Joseph, Xue, Zhenyi, Ciecinski, Sandra, Kavanaugh, Arthur, Nash, Peter, Eldred, Ann, Coates, Laura   +9 more
core   +1 more source

Patient characteristics and minimal disease activity in psoriatic arthritis: a transcontinental comparison

Clinical Rheumatology, 2021
Psoriatic arthritis (PsA) is a heterogeneous disease with both environmental and genetic factors playing a role in this diversity. The aim of this study is to compare the patient profiles and outcomes in PsA patients in three countries from three continents.
Bakirci, Sibel, Ayan, Gizem, Gazel, Ummugulsum, Tinazzi, Ilaria, Solmaz, Dilek, Kasapoglu, Esen, Kalyoncu, Umut, Aydin, Sibel Zehra   +7 more
openaire   +4 more sources

Minimal Change Disease Is Associated with Mitochondrial Injury and STING Pathway Activation [PDF]

Journal of Clinical Medicine, 2022
We hypothesized that minimal change disease (MCD) pathogenesis may be associated with mitochondrial injury, and that the degree of mitochondrial injury at the time of diagnosis may serve as a valuable prognostic marker. We compared urinary mitochondrial DNA (mtDNA) at the time of diagnosis in patients with MCD and age- and sex-matched healthy controls (
Byung Chul Yu, Ahrim Moon, Kyung Ho Lee, Young Seung Oh, Moo Yong Park, Soo Jeong Choi, Jin Kuk Kim   +6 more
openaire   +2 more sources

The duration of remission and minimal disease activity after initiation and discontinuation of biological agents in patients with early psoriatic arthritis (data from the all-russian psoriatic arthritis registry)

Научно-практическая ревматология, 2019
Remission duration and minimal disease activity (MDA) during treatment with biological agents (BA) and after their discontinuation in patients with early psoriatic arthritis (PsA) have been insufficiently studied.Objective: to study the timing of the ...
E. Yu. Loginova, T. V. Korotaeva, S. I. Glukhova, E. L. Nasonov   +3 more
doaj   +1 more source

Minimal disease activity, remission, and the long‐term outcomes of rheumatoid arthritis [PDF]

Arthritis Care & Research, 2007
AbstractObjectiveTo determine the prevalence of minimal disease activity (MDA) and remission in patients with rheumatoid arthritis (RA), to assess the effect of anti–tumor necrosis factor (anti‐TNF) therapy on MDA, and to determine the extent to which MDA status improves long‐term outcomes.MethodsUsing the Patient Activity Scale (PAS) as a surrogate ...
Wolfe, Frederick, Rasker, Johannes J., Boers, Maarten, Wells, George A., Michaud, Kaleb   +4 more
openaire   +3 more sources

Use of a multidimensional RAPID3 questionnaire to assess the achievement of remission and minimal disease activity in patients with early psoriatic arthritis treated according to Treat-to-target strategy

Научно-практическая ревматология, 2019
The current Treat-to-target (T2T) strategy in the management of patients with psoriatic arthritis (PsA) is based on strict control over the dynamics of a patient's status and timely correction of therapy according to the presence or absence of remission ...
E. Yu. Loginova, T. V. Korotaeva, A. D. Koltakova   +2 more
doaj   +1 more source

Effects of Treatment With Risankizumab on Minimal Disease Activity (MDA) and Disease Activity in Psoriatic Arthritis (DAPSA): An Analysis of the KEEPsAKE-1 and -2 Trials

, 2022
Background Risankizumab (RZB) is a monoclonal antibody that specifically inhibits interleukin 23. Objectives To evaluate the achievement of Minimal Disease Activity (MDA), its components, and achievement of Disease Activity in PsA Low Disease Activity
Kavanaugh, A, Ciecinski, S, Mcinnes, I, Nash, P, Stakias, V, Coates, L, Douglas, K, Xue, Z, Eldred, A, Merola, JF, S. Ciecinski, L. Coates, I. Mcinnes, K. Douglas, A. Kavanaugh, Z. Xue, P. Nash, V. Stakias, A. Eldred, J. F. Merola   +19 more
core   +1 more source